Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies.
about
Is There Any Reason to Prefer Cord Blood Instead of Adult Donors for Hematopoietic Stem Cell Transplants?Clinical Implications of Basic Science Discoveries: Microchimerism Finds a Major Role in Reproductive Success; but Does It Also Contribute to Transplant Success?Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancyUmbilical cord blood transplantation: the first 25 years and beyond.Naturally acquired microchimerism: implications for transplantation outcome and novel methodologies for detection.Stem cell microchimerism and tolerance to non-inherited maternal antigens.The pendulum swings: Tolerance versus priming to NIMA.How I treat: the selection and acquisition of unrelated cord blood grafts.Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).Indirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation.Microchimerism in cord blood: mother as anticancer drug.HLA mismatch direction in cord blood transplantation: impact on outcome and implications for cord blood unit selection.HLA-targeted cell sorting of microchimeric cells opens the way to phenotypical and functional characterizationA perspective on the selection of unrelated donors and cord blood units for transplantationGeneration of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.Bidirectional alloreactivity: A proposed microchimerism-based solution to the NIMA paradox.Development of a diverse human T-cell repertoire despite stringent restriction of hematopoietic clonality in the thymus.The Role of HLA in Cord Blood Transplantation.Extensive haplotype diversity in African American mothers and their cord blood units.Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications.Genetics of graft-versus-host disease: the major histocompatibility complex.Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) and Société FrançaTransplantation tolerance to a single noninherited MHC class I maternal alloantigen studied in a TCR-transgenic mouse model.Birth order and transplantation outcome in HLA-identical sibling stem cell transplantation: an analysis on behalf of the Center for International Blood and Marrow TransplantationModification of host dendritic cells by microchimerism-derived extracellular vesicles generates split tolerance.Clinical utilization of cord blood over human health: experience of stem cell transplantation and cell therapy using cord blood in Korea.The great debate: haploidentical or cord blood transplant.On the future of HLA.Umbilical cord blood immunology: relevance to stem cell transplantation.Emerging concepts in haematopoietic cell transplantation.Using HLA typing to support patients with cancer.Cord blood transplant for acute myeloid leukaemia.Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.Impact of HLA in cord blood transplantation outcomes.Donor-derived exosomes: the trick behind the semidirect pathway of allorecognition.Graft predominance after double umbilical cord blood transplantation: a review.Consideration of noninherited maternal Ags as permissible HLA mismatches in cord blood donor selection.Identification of a novel HLA allele, HLA-B*53:39, in a Guadaloupean individual.Human Umbilical Cord Blood Cell Transplantation in Neuroregenerative Strategies
P2860
Q26770210-E1CE33FD-80D9-4092-8CDD-1765DE25E3F0Q26809940-AF183E29-2751-4E66-98E3-9620C7E236CAQ30557220-334D1668-77A5-41A7-8E56-3A4522692638Q34344669-3AF3C166-4090-44F4-9467-2E3B354B65C9Q34352679-D5F29AD4-7183-42AA-A482-4BE88EECC033Q34369195-2E8E6ED1-0F6C-4DA3-8572-E0BF55CCABA6Q34558114-2FE1AA1F-17A8-4376-8BBE-60D0360B9198Q34707580-2D782FCB-303F-4C3F-8A9F-560FD64C7A60Q34749292-DE7A2C28-4581-4284-BDAB-A89023F925B3Q35786957-B46E4D42-5008-4A1E-BACA-13FFC3B9C81FQ35787149-3F81A335-E909-49A3-8154-CD3B6BA69753Q35794126-144058A2-145F-4071-B9C4-5C37BB84E7CCQ35877017-821C055C-61D4-47D3-B2F9-23C4CBA80972Q36100445-BF50E9ED-5923-4F29-97B8-32D613FCD610Q36107961-3003BFCC-4809-468D-9A75-C42F2CFEF007Q36235319-EF22E8ED-7073-4E86-A657-E4F94D1732C8Q36268546-C63CE6B4-0601-4C9E-9C9D-BB272B7048B6Q36336608-98E8CA3B-DD67-47A8-8098-788FE5F5E83FQ36728749-1732D830-97CD-4DE2-8B47-FEFD92CA47A7Q36745209-391BAA59-DD7D-4A42-8AB7-D19505D06FC2Q36746512-77DF0FAE-64C5-43A3-9D51-DB67F5A3F007Q36766250-1D8ABA54-EA7E-4151-9332-95555644E768Q36967170-E58F7C47-501F-4FDA-80F1-9A5EBFCC2919Q37174254-D486C9ED-A93E-45D2-9406-EC71874B0A4CQ37396289-DDAB6BF0-1F5F-496A-9A46-7E919FF8CEC2Q37626249-8FFC5C0C-BFB4-4616-8158-4D3E9445B7B1Q37725142-61FA3494-4322-4C4C-8E32-344FC9AC7EFCQ37806066-4A78DC61-1B17-4266-9FB7-D194C9759578Q37935058-23353DDD-E425-424D-98B3-782B1522A51FQ37963798-F709091A-68D9-4D37-9C47-BDA34251CBD1Q38013047-E2E50406-4691-4C22-826D-79D8C5532BAEQ38287616-236D0991-64FE-4909-8CB9-6AC20BCCB337Q38696346-275DB38B-B928-407F-82BF-9979CE389DECQ38747929-BAA88AF8-5287-4595-A180-DDE42C6FCFC8Q38802750-90C0CE2F-44DF-40DD-9DFA-754EE4A31985Q39023591-A86C2FCC-E3D2-4EB6-B543-1FACFEA71C14Q39368481-EDB9009E-5B56-4DB6-A2CF-FF31AD1E774AQ40818958-41EF53B2-B72D-48A5-B671-CA4378A6CD0BQ41253082-A6E527ED-9996-4983-A1A0-489A943D311AQ41688586-5DC97F98-1543-4F5F-99A7-514E0C46CAAE
P2860
Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Reexposure of cord blood to no ...... in hematological malignancies.
@en
Reexposure of cord blood to no ...... in hematological malignancies.
@nl
type
label
Reexposure of cord blood to no ...... in hematological malignancies.
@en
Reexposure of cord blood to no ...... in hematological malignancies.
@nl
prefLabel
Reexposure of cord blood to no ...... in hematological malignancies.
@en
Reexposure of cord blood to no ...... in hematological malignancies.
@nl
P2093
P2860
P356
P1476
Reexposure of cord blood to no ...... in hematological malignancies.
@en
P2093
Andromachi Scaradavou
Carmelita Carrier
Carol Carpenter
Cladd E Stevens
Jacqueline Smits
Jon J van Rood
P2860
P304
19952-19957
P356
10.1073/PNAS.0910310106
P407
P577
2009-11-09T00:00:00Z